| 新型血小板P2Y12受体拮抗药 |
| |
| 引用本文： | 黄震华. 新型血小板P2Y12受体拮抗药[J]. 中国新药与临床杂志, 2011, 0(8) |
| |
| 作者姓名： | 黄震华 |
| |
| 作者单位： | 上海交通大学医学院附属第九人民医院心血管病研究室; |
| |
| 摘 要： | 抑制ADP诱导的血小板聚集的药物(如氯吡格雷)已成为目前心血管领域内最重要的抗血小板药物。但氯吡格雷起效较慢,抗血小板作用相对较弱,尚有一定的低反应者和无反应者。普拉格雷是一个较新的血小板P2Y12受体拮抗药。TRITON-TIMI 38研究表明普拉格雷可使主要终点发生率(心血管死亡、非致死性心肌梗死、非致死性卒中)降低19%,但使出血并发症增加。坎格雷洛,替格雷洛,依诺格雷是更新的血小板P2Y12受体拮抗药。
|
| 关 键 词： | 血小板聚集 血小板聚集抑制剂 氯吡格雷 普拉格雷 |
New platelet P2Y12 receptor antagonists |
| |
| HUANG Zhen-hua. New platelet P2Y12 receptor antagonists[J]. Chinese Journal of New Drugs and Clinical Remedies, 2011, 0(8) |
| |
| Authors: | HUANG Zhen-hua |
| |
| Affiliation: | HUANG Zhen-hua(Cardiovascular Research Room,the Ninth People's Hospital,Medical College,Shanghai Jiaotong University,SHANGHAI 200011,China) |
| |
| Abstract: | The anti-platelet drugs(such as clopidogrel)that inhibit ADP induced platelet aggregation are the most important drugs for treatment of cardiovascular diseases nowadays.But clopidogrel has the dis-advantage of slow onset,relative low efficacy,and patients with low-response and no-response were reported.Prasugrel was a relatively new platelet P2Y12 receptor antagonist.TRITON-TIMI 38 study showed that prasugrel has a 19% decrease in the incidence of major endpoint(cardiovascular death,non-fatal myocardial inf... |
| |
| Keywords: | platelet aggregation platelet aggregation inhibitors clopidogrel prasugrel |
| 本文献已被 CNKI 等数据库收录！ |
|
